目的 观察唑来膦酸联合化疗治疗非小细胞肺癌骨转移前后血清β-CTX水平的变化及其临床意义。方法 选择 60例非小细胞肺癌骨转移患者，随机分为唑来膦酸联合化疗组（实验组，n=30）和单纯化疗组（对照组，n=30）。观察两组治疗前后血清β-CTX水平的变化。结果 实验组治疗骨转移的有效率为90.00%（CR 9例，PR 18例，NR 3例），而对照组仅为63.33%（CR 7例，PR 12例，NR 11例），差异有统计学意义（P＜0.05）。实验组治疗后血清β-CTX水平较治疗前明显下降，差异有统计学意义（P＜0.05）。而对照组治疗前后血清β-CTX水平差异无统计学意义（P＞0.05）。结论 唑来膦酸联合化疗能够更加有效的降低非小细胞肺癌骨转移患者的血清β-CTX水平，提示血清β-CTX水平的变化可作为唑来膦酸治疗非小细胞肺癌骨转移患者是否获益的指标。

Objective To investigate the clinical significance of βisomer of C-terminal telopeptide (β-CTX) in Zoledronic acid (ZOL) combined with chemotherapy for non-small cell lung cancer (NSCLC) with bone metastasis. MethodsNewly diagnosed NSCLC patients with bone metastasis (n=60) were randomised to the test group (n=30), who received ZOL combined with chemotherapy, or a control group (n=30), who received chemotherapy alone. Serum β-CTX was measured by ELISA before and after treatment in two groups. ResultsThe total effective rate was 90.00% in the treatment group were higher than that of the control group (63.33%) (P<0.05). The level of β-CTX after treatment in treatment group was lower than that before treatment (P<0.05), while in control group had no significant difference (P>0.05). ConclusionZOL administered with chemotherapy can more effectively reduce β-CTX levels for NSCLC patients with bone metastasis. Indicating that the change of β-CTX might be as a valuable index to ZOL for the treatment of NSCLC patients with bone metastasis.